Barbara Kahn Sells 3,000 Shares of DexCom, Inc. (DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Barbara Kahn sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $54.58, for a total transaction of $163,740.00. Following the sale, the director now directly owns 4,353 shares of the company’s stock, valued at approximately $237,586.74. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of DexCom, Inc. (NASDAQ:DXCM) opened at $55.11 on Wednesday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $88.80.

TRADEMARK VIOLATION NOTICE: This piece was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/11/22/barbara-kahn-sells-3000-shares-of-dexcom-inc-dxcm-stock.html.

A number of large investors have recently bought and sold shares of DXCM. Advisor Group Inc. grew its holdings in DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after purchasing an additional 837 shares during the period. Zions Bancorporation grew its holdings in DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after purchasing an additional 3,260 shares during the period. IFP Advisors Inc grew its holdings in DexCom by 30.5% in the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after purchasing an additional 568 shares during the period. Toronto Dominion Bank grew its holdings in DexCom by 251.0% in the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after purchasing an additional 2,608 shares during the period. Finally, Janney Montgomery Scott LLC grew its holdings in DexCom by 9.2% in the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after purchasing an additional 250 shares during the period.

A number of analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $62.00 price target (down previously from $90.00) on shares of DexCom in a report on Thursday, September 28th. Raymond James Financial, Inc. downgraded shares of DexCom from an “outperform” rating to a “mkt perform” rating in a research note on Friday, September 29th. Canaccord Genuity reissued a “buy” rating and issued a $69.00 price objective (down previously from $90.00) on shares of DexCom in a research note on Thursday, September 28th. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research note on Wednesday, October 25th. Finally, ValuEngine raised shares of DexCom from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $70.69.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply